Conavi Medical Hires Outside Help to Court Investors
Toronto-based Conavi Medical says it has signed media and digital marketing agreements to raise its profile. The OTCQB line closed up 10.94% at 0.13 on Sept. 4.

Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) said on Sept. 4, 2026 that it has entered into media and digital marketing agreements intended to increase market awareness of the company, whose OTCQB-listed shares last closed at 0.13, up 10.94% on the day.
Conavi Medical Corp. (OTCQB: CNVIF), which also trades in Canada on the TSX Venture Exchange under the symbol CNVI, told the market on Sept. 4, 2026 that it has entered into media and digital marketing agreements meant to lift awareness of the company. The Toronto-based firm describes itself as a commercial-stage medical device business that designs, manufactures and markets imaging technologies used to guide minimally invasive cardiovascular procedures.
The announcement, carried over Globe Newswire and reported by Financial Post, is a small piece of corporate housekeeping in isolation. But for a micro-cap medical device issuer, the decision to pay for outside awareness work is itself a signal about where management believes the bottleneck sits — and it is not in the operating room.
What the shares did on the day
The OTCQB line closed at 0.13 on Sept. 4, up 10.94% from the prior close of 0.12, with a day range of 0.12 to 0.13. That is a double-digit percentage move expressed in a single cent, which is the arithmetic reality of trading a sub-penny-increment stock: the tick size and the percentage move are effectively the same event. Investors reading a 10.94% gain should hold that context firmly.
The broader tape gave no help. The S&P 500 tracker closed at $770.19, down 0.39%, and the Dow 30 proxy fell 0.53% to $534.08. The Nasdaq 100 tracker was the exception, edging up 0.18% to $718.96. Against a mildly negative session for large-cap benchmarks, Conavi's move was company-specific rather than a rising-tide effect.
Why a device company buys awareness
Conavi's stated business is imaging that guides catheter-based cardiovascular work — the kind of intravascular visualisation an interventional cardiologist uses to place and size a device inside a coronary artery. That is a sale made to hospitals, cardiac catheterisation labs and physicians, through clinical evidence, reimbursement codes and direct field representatives. Media and digital marketing agreements of the kind announced here do not typically move that needle.
What they do move is visibility with investors and, secondarily, with the retail and institutional audiences that follow small-cap Canadian healthcare names. A commercial-stage company with a dual TSXV and OTCQB listing has two shareholder bases in two countries, and the OTCQB tier in particular relies heavily on issuers doing their own communication work: there is no analyst coverage machine attached to it by default.
The practical reading is that Conavi wants to be found. Whether that reflects an approaching financing, a wider distribution effort, or simply a desire to close the gap between commercial progress and share price, the release as summarised does not say.
The terms investors will want and did not get
The summary available does not disclose the counterparties to the agreements, their duration, the fees payable, or whether any portion of the consideration is in shares rather than cash. Those omissions matter more than they would at a larger company. For a micro-cap, an investor-awareness contract paid in stock or warrants introduces potential dilution; paid in cash, it consumes runway that would otherwise fund manufacturing, regulatory work or sales headcount.
Canadian venture issuers are generally required to file the material terms of investor relations arrangements with the exchange, and the TSX Venture Exchange has its own rules governing what an issuer may pay a promotional service provider and in what form. Shareholders who want the numbers should look to the company's subsequent filings on SEDAR+ rather than to the headline.
- Who the counterparties are — whether they are registered investor relations providers or unregistered media vendors.
- How they are paid — cash, shares, warrants, or a mix, and over what period.
- Term and termination — a rolling monthly engagement carries very different economics from a multi-year commitment.
- Exchange acceptance — whether the TSXV has cleared the arrangements.
Shareholders who want the numbers should look to the company's subsequent filings on SEDAR+ rather than to the headline.
What to watch from here
The next informative disclosures are unlikely to be about marketing at all. For a commercial-stage device company, the figures that decide the equity story are revenue growth, gross margin on units shipped, cash used in operations and the size of any subsequent financing. An awareness campaign that precedes a raise is a familiar sequence in the venture market; one that follows commercial traction is a different story entirely. The company's next quarterly filing will show which of those the market is looking at.
Second, watch liquidity. Part of the reason small issuers commission this kind of work is that thin trading volume deters institutional buyers who cannot build or exit a position without moving the price. If the agreements do their job, average daily volume on both the TSXV and OTCQB lines should widen over the coming months. If volume does not change, the spend will have bought little.
Third, watch the spread between the two listings. Dual-listed Canadian micro-caps often see most genuine price discovery on the home exchange, with the U.S. OTC quote following at a lag and in a different currency. A U.S. holder reading only the CNVIF quote is seeing a translated, less liquid reflection of the Canadian market.
The micro-cap context
Nothing in the announcement changes Conavi's clinical position, its product approvals or its installed base. It is a distribution decision about information, not about devices. Investors sometimes treat awareness announcements as catalysts because the share price moves on the day they land — and on Sept. 4 it did, by 10.94%. The more durable question is whether the underlying commercial business generates the revenue that makes wider awareness worth having.
For now, the verified facts are narrow: a Toronto medical imaging company focused on cardiovascular procedures has signed marketing agreements, and its U.S.-quoted shares closed at 0.13. Everything else — cost, counterparty, duration — awaits the filings.
Key facts
- Ticker and last close: CNVIF 0.13, +10.94%, as of Sept. 4, 2026, 20:00 GMT
- Listings: TSXV: CNVI and OTCQB: CNVIF
- Announcement: Media and digital marketing agreements to raise market awareness
- Business: Commercial-stage imaging technologies for minimally invasive cardiovascular procedures
Frequently asked questions
What did Conavi Medical announce?
On Sept. 4, 2026, Conavi Medical Corp. said it had entered into media and digital marketing agreements intended to support increased market awareness of the company. The dated Toronto release did not, in the available summary, disclose the counterparties, the fees payable, the form of payment or the term of the agreements.
Where does Conavi Medical trade?
Conavi Medical is dual-listed. It trades in Canada on the TSX Venture Exchange under the symbol CNVI and in the United States on the OTCQB market under CNVIF. Dual listings of this kind mean two shareholder bases in two currencies, with most genuine price discovery typically occurring on the home Canadian exchange.
How did the shares react?
The OTCQB line closed at 0.13 on Sept. 4, 2026, up 10.94% from the previous close of 0.12, with a day range of 0.12 to 0.13. Because the stock trades at very low absolute levels, a single-cent move produces a large percentage change, so the headline gain should be read with that in mind.
What does Conavi Medical actually make?
The company describes itself as a commercial-stage medical device business that designs, manufactures and markets imaging technologies used to guide minimally invasive cardiovascular procedures. In practice that means intravascular visualisation tools sold to hospitals, cardiac catheterisation labs and interventional cardiologists rather than to consumers.
Why would a small medical device firm pay for marketing agreements?
Awareness agreements at micro-cap issuers are usually aimed at investors rather than clinical customers. Small companies on venture and OTC tiers rarely attract analyst coverage automatically, so they commission media and digital work to widen visibility, improve trading liquidity and make it easier for institutional buyers to build positions without moving the price.
What should shareholders look for next?
The material terms — counterparty names, fees, whether payment is in cash or shares, contract duration and exchange acceptance — should appear in subsequent regulatory filings. Beyond that, the figures that matter are revenue, gross margin, cash used in operations and any financing, plus whether average daily trading volume actually rises.
Sources
- Conavi Medical Announces Media and Digital Marketing Agreements — Financial Post
Photo: Los Muertos Crew · Pexels Licence — source


